Keloid Market

Market Overview:

The 7 major keloid markets are expected to exhibit a CAGR of 2.56% during 2023-2033.

The keloid market has been comprehensively analyzed in IMARC's new report titled "Keloid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033". Keloid refers to a medical condition that occurs when an excess amount of collagen, a protein that forms the connective tissue in the skin, is produced during the healing process of a wound or injury. The excess collagen results in the development of raised, thick, and often irregular scar that extends beyond the borders of the original wound. These scars may range in size from a few millimeters to several centimeters and can be pink, red, brown, or flesh-colored. Keloids may be itchy or tender, and they can cause discomfort or pain. In addition to physical symptoms, they can also lead to emotional distress due to their unsightly appearance and the social stigma associated with them. The diagnosis of the ailment is usually based on a physical exam and medical history. A dermatologist or healthcare provider will typically examine the keloid and surrounding skin for characteristic signs, such as raised and shiny scars that extend beyond the original wound site. The doctor may also enquire about the patient's medical history, including previous injuries or surgeries, and family history of keloids. In some cases, a biopsy may be performed to confirm the diagnosis and rule out other skin conditions. Numerous imaging tests, such as ultrasound, MRI, CT scans, etc., are utilized to evaluate the extent of the keloid.

The increasing occurrences of various skin injuries, including surgical scars, burns, acne, deep cuts, etc., are primarily driving the keloid market. Besides this, the growing prevalence of several cosmetic procedures, such as piercings and tattoos, which can potentially result in keloid formation, is also augmenting the market growth. Furthermore, the widespread adoption of corticosteroid injections for reducing the size of the keloid, making them less noticeable, is creating a positive outlook for the market. Apart from this, the inflating demand for cryotherapy, which involves freezing the keloids with liquid nitrogen, thereby causing the keloid tissue to break down and eventually fall off, is acting as another significant growth-inducing factor. Additionally, the introduction of advanced diagnostic techniques, such as multiphoton microscopy and optical coherence tomography, since they provide high-resolution images of the skin and can help identify the location as well as the extent of keloids, is also bolstering the market growth. Moreover, the emerging popularity of radiofrequency ablation on account of its numerous benefits over traditional surgical excision, including reduced scarring, improved function, and fewer complications, is expected to drive the keloid market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the keloid market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for keloid and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the keloid market in any manner.

Time Period of the Study

• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the keloid market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the keloid market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current keloid marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the keloid market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
• What was the country-wise size of the keloid market across the seven major markets in 2022 and what will it look like in 2033?
• What is the growth rate of the keloid market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2017-2033) of keloid across the seven major markets?
• What is the number of prevalent cases (2017-2033) of keloid by age across the seven major markets?
• What is the number of prevalent cases (2017-2033) of keloid by gender across the seven major markets?
• How many patients are diagnosed (2017-2033) with keloid across the seven major markets?
• What is the size of the keloid patient pool (2017-2022) across the seven major markets?
• What would be the forecasted patient pool (2023-2033) across the seven major markets?
• What are the key factors driving the epidemiological trend of keloid?
• What will be the growth rate of patients across the seven major markets?
   

Keloid: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for keloid drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the keloid market?
• What are the key regulatory events related to the keloid market?
• What is the structure of clinical trial landscape by status related to the keloid market?
• What is the structure of clinical trial landscape by phase related to the keloid market?
• What is the structure of clinical trial landscape by route of administration related to the keloid market?